Pharma Focus Asia

Hillstream BioPharma Signs Option Agreement to Advance Next-Generation Anti-MUC1-C Agents

Wednesday, February 01, 2023

Hillstream BioPharma announced signing an exclusive option agreement with Dana-Farber Cancer Institute to licence technology targeting the MUC1-C oncoprotein.

This agreement allows Hillstream to leverage Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumours, which represents a major unmet need for patients.

Under an exclusive option agreement which, if converted into an exclusive licence agreement, will allow Hillstream to develop anti-MUC1-C antibodies to supply Hillstream's Quatramer-based lead candidate. HSB-1216 targets CSC by inducing ferroptosis. This approach, combineing HSB-1216 for conjugation with MUC1-C antibodies, is highly synergistic in eliminating CSCs, effective for long-term responses and treatments.

MUC1-C is effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung cancer (SCLC), merkel cell carcinoma (MCC) and neuroendocrine prostate cancer (NEPC). MUC1-C is considered necessary for multiple hallmarks of the cancer cell, including (i) the persister cell (PC) state, (ii) drug resistance, (iii) immunosuppression, and (iv) poor clinical outcomes.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024